BullFrog AI Continues to Expand Team with Appointment of New VP of Business Development

$BFRG
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $BFRG alert in real time by email

GAITHERSBURG, Md., June 07, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced the appointment of Toby Sayre, MS as VP of Business Development.

Sayre brings more than 18 years of experience in life sciences and biotechnology consulting, business development, product development, and client engagement to BullFrog AI. He holds master's degrees in Cell and Molecular Biology and Biochemistry from San Francisco State University (SFSU) and University of California, Los Angeles (UCLA), and has a technical background in bioinformatics, biochemistry, real-world data, natural language processing (NLP) and AI software.

"Toby brings a wealth of experience that will be an invaluable asset to BullFrog AI as we continue to expand our reach into the life sciences and biotechnology industry," said Vin Singh, Founder and CEO of BullFrog AI. "We are excited to welcome Toby to our executive team and look forward to the impact he will make on our business strategy and development efforts."

Sayre joins BullFrog AI with a proven track record of success in various roles, including his most recent position as VP of RWE, Value, and Life Science Partnerships at ConcertAI. Previously, during his tenure at Doctor Evidence, LLC, Sayre held several key positions of increasing responsibility, including Chief Commercial Officer, and successfully launched an AI-enabled SaaS product that generated over $2.5 million in annualized contracts within its first quarter. As a strategic leader, he managed the company's commercial pivot from consulting to SaaS, maintaining client satisfaction and achieving 25% year-over-year growth for a $20 million revenue portfolio.

"I am thrilled to join the BullFrog AI team at such an exciting time in the company's evolution, and I look forward to driving innovative solutions and forging strategic partnerships that will solidify BullFrog AI's position as a market leader," said Sayre.

"With the addition of Toby, our expanding team now consists of 13 dedicated professionals, both full-time and part-time employees, as well as contracted consultants, who share a common vision of transforming the drug development landscape," continued Singh.

About BullFrog AI

BullFrog AI is a digital technology company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may seek to receive the therapies they need.

For more information visit BullFrogAI at

Website: www.bullfrogai.com

LinkedIn: https://www.linkedin.com/company/bullfrogai/

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Dave Gentry

RedChip Companies, Inc.

BFRG@redchip.com

800-733-2447

SOURCE: BullFrog AI Holdings, Inc. 



Get the next $BFRG alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BFRG

DatePrice TargetRatingAnalyst
More analyst ratings

$BFRG
Press Releases

Fastest customizable press release news feed in the world

See more
  • BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial

    GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its entry into a collaboration agreement with Eleison Pharmaceuticals Inc. ("Eleison"), a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers. Under the terms of the agreement, BullFrog AI will provide access to its BullFrog Data Networks™ AI solution to enhance clinical trial efficiency and patient insights. Financial terms of the coll

    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BullFrog AI to Present at Biotech Showcase and RESI JPM During JP Morgan Week

    GAITHERSBURG, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its participation in the TechBio track at Biotech Showcase and RESI JPM, both taking place during the annual JP Morgan Healthcare Conference in San Francisco, January 13–16, 2025. At both Biotech Showcase and RESI JPM, BullFrog AI will highlight its proprietary BullFrog Data Networks®, a data insights tool powered by the bfLEAP™ platform. BullFrog Data Networks® eva

    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BullFrog AI Issues Letter to Stockholders

    GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa

    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BFRG
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BFRG
SEC Filings

See more

$BFRG
Leadership Updates

Live Leadership Updates

See more
  • BullFrog AI Issues Letter to Stockholders

    GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in our mission to revolutionize drug development. Your commitment fuels our drive to innovate and achieve transformational milestones. In thinking back on this past year, it is evident that 2024 wa

    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BullFrog AI Announces Appointment of Chief Financial Officer

    GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's former CFO, who recently lost his battle with cancer. "Dane's contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and

    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni

    GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ:BFRG, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades of experience in the pharmaceutical industry, including leadership roles in scientific research and technology-driven drug discovery. Dr. Baldoni's career includes 29 years in R&D at GSK, where he served as Senior Vice President of Platform and Technology Sciences, lea

    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BFRG
Financials

Live finance-specific insights

See more
  • BullFrog AI and GreenPower Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / April 26, 2024 / RedChip Companies will air interviews with BullFrog AI Holdings, Inc. (NASDAQ:BFRG) and GreenPower Motor Company Inc. (NASDAQ:GP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BullFrog AI: https://www.redchip.com/assets/access/bfrg_accessGreenPower: https://www.redchip.com/assets/access/gp_accessIn an exclusive interview, Vin Singh, CEO of BullFrog AI, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corporate u

    $BFRG
    $GP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Construction/Ag Equipment/Trucks
    Consumer Discretionary
  • ASP Isotopes and Bullfrog AI Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / October 27, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG)(NASDAQ:BFRGW) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessBullfrog AI: https://www.redchip.com/assets/access/bfrg_accessPaul Mann, CEO, of ASP Isotopes appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. ASP Isoto

    $ASPI
    $BFRG
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RedChip Launches 'Small Stocks, Big Money' Podcast

    New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money."Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players. The series features in-depth interviews with executives from some of the top names in smaller cap stocks, providing list

    $BFRG
    $LTRN
    $RVPH
    $STSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology